How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

548 results for

Unintentional Weight Loss Causes

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

501. Cost-benefit analysis of first-generation antihistamines in the treatment of allergic rhinitis

care costs avoided and usual activities (e.g. productivity output). Direct costs The quantities and the costs were analysed separately. The total cost of FGA-associated sedation was estimated using the human capital approach for lost productivity and the direct and indirect cost of unintentional injuries and fatalities (including motor vehicle, occupational, public and home). The weighted average cost to society of the average collision ($8,028) included the following main direct costs: medical (...) ). The economic study was carried out in the USA. Dates to which data relate The benefits associated with FGAs were estimated using willingness-to-pay (WTP) questionnaires at 2001 values. Estimates of the incidence of sedation and the economic cost of lost productivity caused by FGAs were derived from a review of the literature. The studies selected were published up to 2003. The costs associated with sedation were based on data from the National Highway Traffic Safety Administration (NHTSA), with injuries

2004 NHS Economic Evaluation Database.

502. Management of dyspepsia in adults in primary care

use. - Urgent specialist referral for endoscopic investigation. is indicated for patients of any age with dyspepsia when presenting with any of the following: chronic gastrointestinal bleeding, progressive unintentional weight loss, progressive difficulty swallowing, persistent vomiting, iron deficiency anaemia, epigastric mass or suspicious barium meal. - Routine endoscopic investigation of patients of any age, presenting with dyspepsia and without alarm signs, is not necessary. However (...) for Clinical Excellence (NICE) 2004: 45 Authors' objectives This report provides guidelines on the management of dyspepsia in adults in primary care. Authors' conclusions The following have been identified as priorities for implementation. Referral for endoscopy - Review medications for possible causes of dyspepsia (for example, calcium antagonists, nitrates, theophyllines, bisphosphonates, corticosteroids and non-steroidal anti-inflammatory drugs [NSAIDs]). In patients requiring referral, suspend NSAID

2004 Health Technology Assessment (HTA) Database.

503. Natural Orifice Translumenal Endoscopic Surgery for intra-abdominal surgery: a systematic review

Table 3: Sites chosen for NOTES viscerotomy 21 Table 4: NOTES gastrotomy closure 24 Table 5: Success of visualisation using NOTES 27 Table 6: Success of NOTES anastomosis creation 32 Table 7: Success of NOTES cholecystectomy 33 Table 8: Success of NOTES biopsy 34 Table 9: Duration of Surgery 38 Table 10: Post-operative mortality 39 Table 11: Post-operative feeding and weight gain 40 Table 12: Infection-related complications 41 SAGES 2006 Abstracts 69 Excluded Studies 75 - ASERNIP-S REVIEW OF NATURAL (...) randomised trials or from at least one high quality randomised controlled trial of sufficient power. The component studies should show consistent results, the differences between the interventions being compared should be large enough to be important, and the results should be precise with minimal uncertainty. Average Most of the evidence is from high quality quasi-randomised controlled trials, or from non-randomised comparative studies without significant flaws, such as large losses to follow-up

2007 ASERNIP-S

504. Eating disorders toolkit, a practice based guide to the inpatient management of adolescents with eating disorders, with special reference to regional and rural areas

professionals’ perception of the problem and immediate concerns ? Current symptoms present and duration of symptoms ? Current severity of symptoms ? Young person’s percept ion of the problem Assessment of safety issues ? Medical safety assessment would in clude assessing results of blood tests, blood pressure, heart rate, temperature, rate of weight loss (if present), and current BMI/BMI Centile (see “Indications for Hospitalisation”). ? Psychological safety issues would in clude risk of self-harm (...) and past treatment ? BN with out of control vomiting ? Vomiting more than 4 times a day ? Weight loss of >1kg/week for four weeks Assess psychiatric comorbidity, e.g., depression, OCD, psychosis ? Moderate to high suicidal ideation ? Active self-harm Risk assessment of suicidality, self-harm and harm to others ? Moderate to high agitation and distress ? Other psychiatric condition requiring hospitalisation Other ? Aversive family relations hips or severe family stress or strain Eating Disorders Toolkit

2008 Clinical Practice Guidelines Portal

505. Comorbidity of mental disorders and substance use

. Alternatives should be offered where appropriate. If the combination is to be administered, the individual should be monitored to confirm interactions and adjust treatment if necessary. 8 THEORETICAL Based on pharmacokinetic and pharmacodynamic properties of the drugs, there is a theoretical possibility that they may interact to cause a different effect if the drugs were administered individually OR in vitro, or animal studies suggest that there may be an interaction. Individuals taking these combinations (...) of drugs should be monitored. | 3 Management of people with comorbidity of mental disorders and substance use Chapter 2 2 Management of people with comorbidity of mental disorders and substance use Mental disorders and substance use occur together very frequently and can interact negatively on one another. Little evidence is available to allow advice about safe levels of substance use in people with mental disorders. Safe levels of consumption in the general population may cause severe adverse effects

2008 Clinical Practice Guidelines Portal

506. Nursing Management of Hypertension

give any guarantee as to the accuracy of the information contained in them nor accept any liability, with respect to loss, damage, injury or expense arising from any such errors or omission in the contents of this work. The views expressed in this guideline do not necessarily reflect those of the Ministry of Health and Long-Term Care. Any reference throughout the document to specific pharmaceutical products as examples does not imply endorsement of any of these products. Copyright (...) ) Diet . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .108 Appendix I – Reducing Sodium the DASH . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 112 Appendix J – Recording Food Habits and DASH . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .115 Appendix K – Canadian Body Weight Classification System . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .116

2005 Registered Nurses' Association of Ontario

507. Effectiveness reviews in health promotion

of effort and to ensure that new reviews build on previous reviews. ? Clear reporting of review methods should be encouraged. For example, a checklist could be provided to authors and journal editors covering the key stages in conducting a systematic review (methods for searching, inclusion criteria, validity criteria). ? Those commissioning and conducting effectiveness reviews should agree a common framework for how reviews in health promotion should be carried out, including the weighting of primary (...) for implementing search strategies and sorting the search results can be reduced by using search strategies with higher specificity. Consequent loss of sensitivity can be minimised by combining a comprehensive search based on subject- and prevention- related terminology with specific study design. This was found to be an acceptable strategy on Medline, but loss of sensitivity may be more severe on other databases especially those with a less comprehensive or no indexing system for study design. The use

1999 EPPI Centre

508. Risk Assessment and Prevention of Pressure Ulcers

liability , with respect to loss, damage, injury or expense arising from any such errors or omission in the contents of this work. Any reference throughout the document to specific pharmaceutical products as examples does not imply endorsement of any of these products. Copyright First published in 2002 by the Registered Nurses’ Association of Ontario. This document was revised in March 2005. With the exception of those portions of this document for which a specific prohibition or limitation against (...) , therapeutic positioning, support surfaces, and other non-pharmacological interventions. Monitor level of pain on an on-going basis, using a valid pain assessment tool. 3.3b Consider the client’s risk for skin breakdown related to the loss of protective IV sensation or the ability to perceive pain and to respond in an effective manner (e.g., impact of analgesics, sedatives, neuropathy, etc.). 3.3c Consider the impact of pain on local tissue perfusion. IV *See page 14 for an Interpretation of Evidence.3.4

2002 Registered Nurses' Association of Ontario

509. Evaluation of S-adenosyl Methionine (SAM-e) for Recurrent Abdominal Pain in Children

in the stool secondary to hemorrhoids is not an exclusion criterion). Unintentional loss of over 10% body weight over the past 3 months or weight < 100% ideal body weight. Recurrent fevers (T>100F) at least once a week or with abdominal pain episodes. Recurrent dehydration with abdominal pain episodes requiring intravenous rehydration. Current personal diagnosis of depression or report of suicidality, mania or bipolar disorder. Family history of mania or bipolar disorder. Current use of opiates or other (...) . For general information, Layout table for eligibility information Ages Eligible for Study: 8 Years to 22 Years (Child, Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: No Criteria Inclusion Criteria: 8 to 22 years old Diagnosed with RAP as verified by a physician, and having at least twice weekly episodes of abdominal pain which cause the patient to withdraw from normal activities. At least one month trial on a high fiber diet without resolution of abdominal pain. Ambulatory Exclusion

2008 Clinical Trials

510. Cetuximab Plus Conformal Thoracic Radiotherapy in Patients (Pts) With Inoperable or Unresectable Locally Advanced Non-Small Cell Lung Cancer (LA

not specified). Eligible Stages: Stages IIA through IIIA disease if it is felt that they are not candidates for possible resection, medically or otherwise. Stage IIIA (multi-station mediastinal lymph nodes) and stage IIIB disease without significant pleural effusion (metastases to contralateral mediastinal or supraclavicular lymph nodes) are also eligible. Age ≥ 70 OR Eastern Cooperative Oncology Group (ECOG) performance status (PS) = 2 at time of registration OR weight loss ≥ 5% in the preceding three (...) of a combination of thoracic radiotherapy with cetuximab, given together, and followed by chemotherapy with docetaxel and cetuximab (also given together) will kill the cancer cells in the patient's body and shrink the size of their tumor without causing unacceptable side effects. This may allow patients to live longer or decrease the frequency and/or severity of the symptoms caused by the cancer without increasing the frequency and/or severity of the symptoms caused by the treatment. Condition or disease

2008 Clinical Trials

511. Therapy of Chronic Lymphocytic Leukemia With Dasatinib (BMS-354825)

lymph nodes, nodal clusters, or progressive lymphadenopathy; Grade 2 or 3 fatigue, fever >/= 100.5 degrees F, night sweats for > 2 weeks w/o documented infection, presence of weight loss >/= 10% over the preceding 6 months; Progressive lymphocytosis with increase in lymphocyte count of >/= 50% over a 2-month period or an anticipated doubling time of < 6 months. Serum bilirubin less than 2mg/dL, serum creatinine less than 2mg/dL unless abnormality is considered due to CLL by investigator. The Eastern (...) Cooperative Oncology Group (ECOG) Performance Status < 3. Patients must sign an informed consent indicating they are aware of the investigational nature of this study, in keeping with the policies of the hospital. Sexually active women of childbearing potential must use birth control during study in manner that risk of failure is minimized. Prior to study enrollment women of childbearing potential must be advised of importance of avoiding pregnancy during trial and potential risk factors for unintentional

2006 Clinical Trials

512. Growth hormone treatment improves peripheral muscle oxygen extraction-utilization during exercise in patients with human immunodeficiency virus-associated wasting: a randomized controlled trial. Full Text available with Trip Pro

)) relationship. We investigated the impact of recombinant human GH (rhGH) treatment on a-vO(2) difference and the Q-VO(2) relationship during submaximal exercise by randomizing 12 HIV-infected patients (mean +/- sem: age, 43.3 +/- 1.5 yr; body mass, 69.5 +/- 2.9 kg; body mass index, 22.4 +/- 0.9 kg/m(2); maximum oxygen consumption, 33.6 +/- 1.5 ml/kg x min), with documented unintentional weight loss (>or=10% within the preceding 12 months) despite antiretroviral therapy, to receive 3 months of rhGH (6 mg/d (...) Growth hormone treatment improves peripheral muscle oxygen extraction-utilization during exercise in patients with human immunodeficiency virus-associated wasting: a randomized controlled trial. The arteriovenous oxygen difference (a-vO(2) difference), a measure of peripheral muscle oxygen extraction-utilization during exercise, is reduced in antiretroviral-treated patients with human immunodeficiency virus (HIV), thus causing a shift in the cardiac output-oxygen consumption (Q-VO(2

2004 The Journal of clinical endocrinology and metabolism Controlled trial quality: uncertain

513. S0429: Docetaxel, Cetuximab, and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer

OR Zubrod performance status 2 with no co-morbidities or meeting 1 of the following criteria: No co-morbidities FEV_1 < 2 L OR < 1 L with estimated contralateral FEV_1 ≥ 0.6 L DLCO > 10 mL/mm Hg/min Albumin < 0.85 times lower limit of normal Unintentional weight loss > 10% within the past 6 months Controlled congestive heart failure which, in the opinion of the investigator, may become decompensated due to radiotherapy FEV_1 < 2 L OR < 1 L with estimated contralateral FEV_1 ≥ 0.6 L Absolute neutrophil (...) form the date of enrollment until the date of death due to any cause. Patients last known to be alive are censored at the date of last contact. Progression-free Survival. [ Time Frame: At week 10, week 22, and then every 3 months until progression for up to 3 years after enrollment. ] Duration from the date of enrollment until the date of progression (as defined by RECIST: >= 20% increase over baseline in the sum of longest diameters, or appearance of new lesions, or non-measurable disease

2006 Clinical Trials

514. Gemcitabine or Gemcitabine Plus Docetaxel After Cisplatin, Etoposide and Radiation in Non Small Cell Lung Cancer (NSCLC)

, Older Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: No Criteria Inclusion Criteria: histologic or cytologic proof of single primary non-small cell lung cancer No prior chemotherapy or radiation therapy no prior malignancy Exclusion Criteria: pregnancy or breastfeeding serious concomitant systemic disorder unintentional weight loss greater than 10% Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may (...) Survival [ Time Frame: 2 years ] Secondary Outcome Measures : Number of Patients With Overall Tumor Response [ Time Frame: randomization and every 3 months up to 2 years of post-study followup ] Progression-Free Survival [ Time Frame: baseline to measured progressive disease up to 2057 days ] Overall Survival [ Time Frame: baseline to date of death from any cause up to 2057 days ] Lung Cancer Symptom Scale (LCSS) Assessment Post-randomization [ Time Frame: baseline to 3 months after last dose of study

2005 Clinical Trials

515. Ghrelin in Older Women

" will increase levels of growth hormone in the blood and increase appetite. Ghrelin is a naturally occurring hormone that is produced mostly by the stomach and causes secretion of another hormone called growth hormone. It also increases short-term appetite and may lower the amount of inflammation in the body. Some people lose their appetite as they age and have unintentional weight loss. This may be caused by a break in the communication between the stomach and the brain. We are particularly interested (...) Ages Eligible for Study: 70 Years and older (Older Adult) Sexes Eligible for Study: Female Accepts Healthy Volunteers: Yes Criteria Inclusion Criteria: Frail group: Women aged 70 or greater Able to give informed consent Undiagnosed weight loss (>5% over the previous year) Two of the following four criteria (from Fried L et al, 2001): low grip strength, slow walking speed, subjective exhaustion, low levels of physical activity Healthy group: Women aged 70 or greater Able to give informed consent

2007 Clinical Trials

516. Ofatumumab + Chlorambucil vs Chlorambucil Monotherapy in Previously Untreated Patients With Chronic Lymphocytic Leukemia

); unexplained, unintentional weight loss >= 10% within the previous 6 months; recurrent, unexplained fever of greater than 38 degrees celsius or 100.5 degrees fahrenheit for 2 weeks; and extreme fatigue. The best response refers to overall best response in terms of CR, CRi, PR or nPR. Data are presented for constitutional response= yes and no. Number of Participants With a Human Anti-human Antibody (HAHA) Positive Result [ Time Frame: Baseline, Cycle 4 Day 1, 1 Month Follow-up, and 6 Month Follow-up ] Serum (...) Outcome Measures Go to Primary Outcome Measures : Progression-Free Survival (PFS), as Assessed by the Independent Review Committee (IRC) [ Time Frame: From randomization until the 259th PFS event occurred (Median follow-up approximately 29.3 months) ] PFS is defined as the interval of time between the date of randomization and the earlier of the date of disease progression (PD) and the date of death due to any cause. PD requires at least one of the following: lymphadenopathy, appearance of any new

2008 Clinical Trials

517. Ph. I Dasatinib/Protracted Temozolomide in Recurrent Malignant Glioma

effects include vomiting, diarrhea, anorexia (loss of appetite), fluid retention, fatigue, headache, rash, hypocalcemia (low calcium level), and decreases in blood counts. Other possible side effects may include nausea, joint pain, muscle aches, generalized pain, abdominal pain, and fever. Rare side effects may include QTc prolongation (heart beat changes), pulmonary edema (fluid around the lungs), difficulty breathing, cough, hemorrhage, gastrointestinal bleeding, pneumonia, cardiac effusion (fluid (...) with a low-molecular weight heparin will be allowed to participate, however oral warfarin is not permitted except for low-dose warfarin (1mg po DAILY), Creatinine < 1.5 x ULN, Serum Na, K+, Mg2+, Phosphate and Ca2+ > or = to Lower Limit of Normal (LLN); An interval of at least 2 weeks between prior surgical resection (1 week for biopsy) and initiation of study regimen; An interval of at least 12 weeks from completion of standard, daily XRT, unless one of the following occurs: a) new area of enhancement

2008 Clinical Trials

518. Bedside Assessment of Fall Risk in Emergency Department Elders

in order to find out how predictive the balance tests are in determining the risk of future falls. Condition or disease Accidental Falls Detailed Description: Falls are one of the most significant health risks to older Americans. In the U.S., 30-60% of community dwelling elders will fall each year.Studies have found rates of serious injury among elders who fall to range from 5-24%. Five percent of those who fall are hospitalized. Among elders, falls cause 2/3 of the deaths due to unintentional injury (...) , the 6th leading cause of death in this age group. Additional major morbidity due to falls includes loss of independence as well as anxiety due to fear of falling. This results in limitation of function and often in a requirement for long-term care. Up to 40% of nursing home admissions are due to falls or fear of falling. Expenditures for fall-related injuries account for 6% of all medical expenditures in geriatric patients. Several interventions have been proven effective to reduce rates of fall

2007 Clinical Trials

519. Study of GTx-024 on Muscle Wasting (Cachexia) Cancer.

note that previous therapy with testosterone and testosterone-like agents is acceptable with a 30 day wash-out. However, if the previous testosterone therapy was a long-term depot, within the past 6 months, the site should call the medical monitor for this study to determine appropriate washout period.) Currently taking megestrol acetate (MEGACE®), dronabinol (MARINOL®), or any prescription medication intended to increase appetite or treat unintentional weight loss Contacts and Locations Go (...) to shorter survival, decreased response rates and increased toxicity to chemotherapy, weakness, and an overall decreased quality of life (DeWys et al. Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. Am J Med. 1980 Oct;69(4):491-7). The purpose of this study is to assess the efficacy of GTx-024 on total body lean mass. Secondary endpoints include but are not limited to assessment of GTx-024 on muscle function, total body weight and total body

2007 Clinical Trials

520. Internal Radiation Therapy in Treating Patients With Liver Metastases From Neuroendocrine Tumors

progression with either of the following manifestations: Moderate-severe right upper quadrant pain and unintentional weight loss > 10% Decline in Karnofsky performance status > 10 points At least a 20% increase in the sum of the longest diameters of target lesions in the liver within the past 12 months No more than 75% replacement of normal liver by neuroendocrine tumor No more than 20% arteriovenous lung shunting on a technetium Tc 99m macro-aggregated albumin nuclear scan No equivocal, nonmeasurable (...) , 2012 Sponsor: Vanderbilt-Ingram Cancer Center Collaborator: National Cancer Institute (NCI) Information provided by (Responsible Party): Steven Meranze, MD, Vanderbilt-Ingram Cancer Center Study Details Study Description Go to Brief Summary: RATIONALE: Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. PURPOSE: This phase II trial is studying how well internal radiation therapy works

2007 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>